The field of Transcatheter Aortic Valve Replacement (TAVR) is expanding quickly. These techniques effectiveness and short term safety have both been thoroughly researched. The long term safety of these gadgets, however, is not well understood. One predicted long term consequence is stroke and guidelines for treating both aortic stenosis and selecting antithrombotic medication following TAVR may be affected by an increase in stroke rates. The main goal was to compare the risk of stroke in the general population with the incidence of stroke up to 8 years following TAVR implantation. Studying late stroke risk variables and post-stroke outcomes were secondary goals. A comprehensive, open label study of patients who underwent TAVR in Sweden between 2008 and 2018 was conducted. The TAVR registry, the in Sweden between 2008 and 2018 was conducted. The TAVR registry, the stroke registry, and the diagnostic registry were the three national registries on which the study's data was based. Stroke incidence 30 days or more after TAVR implantation was the primary outcome, and it was compared to a standard incidence. In a cohort of individuals with similar ages and sexes, the annual risk for stroke ranged between 2.0% and 3.1% as opposed to 1.5% and 1.9%. Reduced renal function, diabetes, a history of stroke, advanced age, and male sex were risk factors for having stroke. The stroke mortality rate after one year was 44%. The results of this study showed an increased rate of stroke following TAVR, but they also indicated that this may be partially explained by the group's higher prevalence of predisposing risk factors.